Suyan Li

Senior Scientist at Stratus Therapeutics

Suyan Li has worked in the scientific field since 2011. Suyan began as a Research Fellow at McLean Hospital, where they identified expression of serine racemase (SR) and synthetization of D-serine in primary astrocytes, established an AD mouse model, isolated and cultured primary neuronal, astrocytes, and microglia cells, and trained laboratory members. In 2018, they joined Eisai US as a Senior Researcher, where they focused on pre-clinical study and early drug development of Alzheimer disease, assessed/characterized biomarker in mouse and human plasma/serum/urine, successfully optimized several IHC/IF antibodies, developed FISH/CISH protocols, performed digital morphometric analysis, presented study results, authored study reports, and more. In 2019, they became a Scientist and then a Principal associate scientist at Sigilon Therapeutics, Inc. In 2022, they will become a Senior Scientist at Garuda Therapeutics.

Suyan Li has a Doctor of Biology degree in Neuroscience and Molecular Biology from the Institute of Radiation Medicine in Beijing, China.

Location

Belmont, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Stratus Therapeutics

4 followers

Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution.


Employees

51-200

Links